Quarterly report pursuant to Section 13 or 15(d)

EQUITY - Summary of Equity Instruments Other than Options (Details)

v3.24.1.u1
EQUITY - Summary of Equity Instruments Other than Options (Details) - $ / shares
 1 Months Ended 3 Months Ended
Feb. 29, 2024
Mar. 31, 2024
Nonvested, Number of Shares    
Granted (in shares)   2,050,000
Warrants    
Nonvested, Number of Shares    
Issued and outstanding at beginning of period (in shares)   86,931,558
Granted (in shares) 1,800,000  
Issued and outstanding at end of period (in shares)   88,981,558
Weighted - Average Exercise Price    
Issued and outstanding at beginning of period (in dollars per share)   $ 1.12
Granted, weighted-average per share grant date fair value (in dollars per share)   0.97
Issued and outstanding at end of period (in dollars per share)   $ 1.12
Exercisable    
Nonvested, Number of Shares, Exercisable (in shares)   86,946,558
Weighted - Average Exercise Price, Exercisable (in dollars per share)   $ 1.12
Warrants | Non-Derivative (Equity) Warrants    
Nonvested, Number of Shares    
Issued and outstanding at beginning of period (in shares)   49,068,636
Granted (in shares)   2,050,000
Issued and outstanding at end of period (in shares)   51,118,636
Exercisable    
Nonvested, Number of Shares, Exercisable (in shares)   49,083,636
Warrants | Derivative Liabilities Warrants    
Nonvested, Number of Shares    
Issued and outstanding at beginning of period (in shares)   37,862,922
Granted (in shares)   0
Issued and outstanding at end of period (in shares)   37,862,922
Exercisable    
Nonvested, Number of Shares, Exercisable (in shares)   37,862,922
Restricted stock    
Nonvested, Number of Shares    
Issued and outstanding at beginning of period (in shares)   1,861
Issued and outstanding at end of period (in shares)   1,861